HUE032720T2 - Piridinil- és kondenzált piridinil-triazolon származékok - Google Patents
Piridinil- és kondenzált piridinil-triazolon származékok Download PDFInfo
- Publication number
- HUE032720T2 HUE032720T2 HUE14719130A HUE14719130A HUE032720T2 HU E032720 T2 HUE032720 T2 HU E032720T2 HU E14719130 A HUE14719130 A HU E14719130A HU E14719130 A HUE14719130 A HU E14719130A HU E032720 T2 HUE032720 T2 HU E032720T2
- Authority
- HU
- Hungary
- Prior art keywords
- mmol
- triazol
- isoquinolin
- oxy
- give
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (5)
- Szabadak»! lg#f í.mbeoktö^ilőSk.kaïiïîiïk ra«K*me^ vagy & vegyük:! s&gy tautomer gyögysss.&tilag eHbg&dfeaw sbj* »hob H' lekötése hldropé«, htsloeRo.-t'\ 0, :A*k k\ , hstoalM es -HR ! ks-xk t^Wtott., k.:> és:R5 ielebtéxe-egymâstôl feggetonel hidrogén, halogdB, -CH. R’é·* H kősói vAssto«, vsgy h es K uml-c; sséoaioituosl egyßth amelybe* ioipesoäikjn«h. beo^Ut) unk vagy pindmgyurfit maotnsk» khôl :a Hsiok^î.«;· iiv’; exeRvo s£Vibx.oe<ok .ys-oer egsota-so' Rlpgetk'Olő a kvxetks èk k>N-'*ü * kAstott s^jhs;aitoen?s«b halogén, -CH, R" ês R\ es λ ninoiogyürü ado« exeifeen s/tibsaitoâU egy-hAssy ;g ksR<:-;ke?:ôic kövül egytotistoi fllgyrsokk vskssstou srobsifitoeoss*!· halogén, R. N, R‘ és R , K" képletesütő ka£\ o!\ki<í j\ ü « de< k jélenlvr; <>-. -CH:0- és -NtR^)- Will! tálaskor!; R"' íeientésc -CHRR’ és etetni kősül salasrok, atnsly atloő esőiben ssobsiíkoák egv-hamm. o kővetkezők RóíüI egymásod íugöyRentU váiassrtöő s/d>xsti;oem;sel; balogén, első» és Id; és üs C gi sslkli kb/al s jali^áéiaa· és R*% és RKÍ. »»íl á-:n«mgéyi60^«»ií faalnalbmoldbi R*5', R* és R"4 ka csolódik. pimdküngyftrőt vagy pipendiogyikoi äü, ahol mindegyik gyűrű adóit esetben ssAsrikoáli egydmh s kővetkezők kőiül egymásstál 1^«ÖeÄ^ilas^#tt:.s^kaiÄ««s««l·: halogén, ÉpÖ&% láiőái|l!|yá|y: !b> Kijelentése hidrogén es C:.., Ad kőről választott, RVl jelenese tottosgvm L jelentése -NéR^V és 1V": és R'1', azokkal a x?:éiiaío;nokkas és nibogentoomnod együtt. amelyhez testire lT!\ l'C'1 es Rw kapcsolódik pas olkhoyo nun vaey rb'»-" xbiigs és ót dkot. ahol tnimkgysk «vor« adv-ü e^etK-n s«Rwtttnait *g$ -has, a kővetkezők kősül e£.yo\asiói Rlgyodenül vakeszkot sisüïseîisoeoàsélrkalog^yE^i All és Cu bab^îflii -A (c) R44 jeientése indfögla, R* jelentése hidrogén él CM akii közt» xá;aaztod; asnenttyibett L je jeniét és R4*' és R'\ azztti a oitrogétsaíototnítt és syen&totnokkal egkit!, amtbsh-sz tvnöfe R!'' «< (H'; kapesoiddik, pinobdmgs ürül x agy ptperidingySrúr átkot ahol mindegyik ». v» samt evében rzobszüntä-t egy-hat, a OXv \0<<»ν, v tói 0 \1~ H tH$gv 0 ' a Un An Ov'"V ' dm f i\ V» ' W Λ" iv;s:îsîv huk'ogety bakn-ao es O,, &Kîi i unt xekuzVé mindegyik rpl»e ag>máMéS m^basul -OI^ -N(R')R\•NRsC(0}R>> -NHC(0)HRs!e, -HK*C{0)NRR*, -CCOIR4, C(0}0Rs; -C{0'>H(RÂ,>Rÿ, -C<0}R<RpORŸt ••CtOMR^StöVRR >^|Rs?R(P)Ä -Jim ~S{0)Rb -<RÖ}sir és --SCO^NCRW kösöl választó«; mindegyik R? jelentése egymástól fbggetktntti & következők közöl választóit- >a) C :<·. nlkii, C;.« aikentí és C..:, alklod, amelyek mindegy Re <*dott esetben szulmliltiáH egy-öt, a kö vétkeik közül egy tnàstôi ídggetknül vám^ztóo szöbsztitóenssel: ksbgén, -»\o, -CR és « "k és i\'ï V . vik\ '.ksl R ’kV í, xui R'H '\ X VN IfcK <.>zt*t .s a Hm í't u ,rxuRA mindegyike adod esetbe« gzyhxzt boáit egpdis a kö^d|ggdk kölgl agynxdsféi |Rggödea|| választod »ZKbs«itaem.stil: balogé». oxo. -ON. Rs># Ç j^jipt, sÄy'^ög. Jetben sztubsztitoák egy-dg a következük közöl egymásról föggei lenöt exo. ~CR de R:w; tnitsdegyik R* és R* jelentése egymásból tbggétlMö! |.MÄii'lÄ;iSiPP^ is) hkltx>g«nt id) C.... alkíl, C;:,* ai keni t és C:,í. aiketil, amelyek mindegyike adott esetben szohszs suták: egy-ö« a kOvrnj..<<zök kíkíöí egvmästbl fOggetienlii vmaszlo t » ah tituervsek betege» exo, k R es RPét (cí t? ,ö dkioalkikai2)«.N <4 :, erÜ-iCH^-, l*„ hefcrocikka-iOiyW· és heteroeriWCH^ mm%é. nbndegvike adott esőiben s?.»bsztR«áli egy-öö a kSvolkex&k közti! egymástól föggctl^Dl választód sKuRaissIliisnssyd totógéíg px% -klói, R;? és €\* a!k)ir amely adón -eseiben Skuksasünéü agNy-ó% ή kóxei-keinlk közöl egymástól Rlggatlenül eáiasztoit, saabsztirnenssek balogén, oxo, -CN és R:”; inimleevik RÍS jeksRése egytnástól filggeiienrd a kővetkezők kózól valasakai; -OR". -NíRu)R". -RíH'!)C-íO)R!\ -MHCV>}NRï!Rs:, .NR‘!t-(0)NHR52. -U'dsR'5, -CfOíOIRk -aO'.M.R'hií:;, -QOIMíR^KIR'-, X > í \ A \<' s ^ : b>v, xOA s- ''ON ' ^ dtitnlees ik R!î es RK jelemébe egy mádtól fágamienllí a I·Clvelkeabk ko.vóll vásmodod,. 'at hidrogén; és veH «*k e»t' vKxxikmxikK anmkek n ' kíjr v k '. s nK ' ^ *v ztm ab α» d >'UV<A közói esí)t»Sötól biggstknin választón: szubsidilaetissek balogén. om>, -Cbk "OH és -MH.g nndej^'k R \Rtxa'v v^n t'd1 )t^ nktx i kosok'ok k'v 0,ιν<.<'Λ H vek ukvdk - <CIÍ5VoSi»''^^ t'őb'Kkaytk' adóit eselbett szubs.'itUtait egy-on v» k''vstkc?ák >v>.'o) egyt'.akot Reget' leni)! válaszKílt sztsbsstkuettsss·! halogén, ó'.o. -CK. Ό.Η és -KH;, t txka' k R 4 't V vv >*.x xt s ivójáét las Xs \ 'k ken ! só ^ x '* 's ^ tixi| gs 0fcí: :.ikKí- aikil: és mlí-de-.o- lk m ét-éke egyn-éstö; fxiggetiettöl a kővetkezők kttzü] választott: 0, R k 3 és % év n t.,N es R t x?w u’O dtstvo v''m" s iis.H' V s t ή\Ι Oggvts^ki egx t e,k be o onosts X V» óvá "t sy VX k s et » ' ;'<.·!; x >> n Xsb"" kgm H ink Ν' tk\X kö, v v sUsZtotS. ................. .pmmmmmt
- 2. As: L Igényem szériád vegyíti«*, l*wtó8Ka· vagy p^toteîS|-Â|8^iSg·^ ahol R’ hidK%e?:. λ Az %én>-p*R#c *»*»* ***« ^gvdkh mW* ^ ^toiiag díosadhaíd iá, múl R< ès R\ ajkkal ö sséoafemokkal *&««. amelyek k«p«##tek teflzolgyüröt wv {*Mfee*ri» .hko«#. ahol 3 lw#« *fed u^8 muK*uöw* *v> *«#:># h#^koioh U««l β******! v^sssto« urimtáueaiael: halogén, -CkL R*'és R* ** a í*rtf!«gytor& **W uotbon ^ubwHwáU egy-l^om, λ Kow'tktfÄÖk kösd ag.us’^H-i fhg^ífeshí yhk^iSOR hidogs'«. *- R ^ H
- 4. Az «fessa Igénypontok bámídysM dhsgÄRd s# ah# R^jçlentéiî« sxobsssttaákdaB efcnll. s,.a*« idwposífek bármelyike uotai veg»*l*· *««»» víí»> »**>**»0« dfogadMö #S, «tel hl# -|ét$$éé& horogé«, R"' jeleni#? hklrogéB 4:¾ Q~'. !#;ΐ ν*Λ»««αΗ, «Otóanyiben \ }<?>e«te*«: •tMÍR^h.és R4*'axswtl anim)@faateK9elés saRsato^md 3##h ansesysK-* s'esui;« R\ R '0¾ H Kspcsy-iMh, plm>hd«^» .wgy éh# mindegyik györó »do« «?.«#** sssuH/iteaU egy-ís.n « kovsikesök fög&ÄÜI hrtttfe, 0, a «*K ^ *-V..« hafealkil. a, A«: ? igénypont steril# vegyokd- feotomer vág) gyógyás/aoiag ej&gádbao #h-ahol R «« â γ«£&ίί a î>ÎttogO'\îîoiî>:'«al λ> sië«aîyt«m.d α-λίοΐ sine K he.' swuife R\ R ' v>> k kapesyR## rj>n'h.y%>«s;u ,okoi am«îy ado« «selten egv-nfey. egymást# «iggntle«# y*N»tots as«toltu«BSSsl szutextituált a követlek khzük hafeggr-. Ch.i aikil es hsjosIRil 7> λχ 5. a#m eotelya R'“' sis R^ a!k# S2âs! s öiirsgdsäfe^kspl Is sÄÄsnmsR hfffRR iR?s|ys>ex tcsfM- R h R' #s :R ' ksspesc-UAhk. szofenfekdallssi. R As sRïsé lgêri>|K»«ok bármelyike »«értei vegyidet «antonier vagy gyegyâssaolsg «Uogadhaîô sb. ahol I jt'ieîsSv.rt.' -NiR^K R. A? i-' äyef>>poaäyk Ky'ï^'RRe sAî«iS^c^olot. saofo^e· ^<%> ásítsd fR s-SVySvhak- A..5# L j«l(Mtifô8ô d>>, t<) \ I i > s i a ' » «' V <v ' i \A <. î'' s IK J. va.-A,-s..A, < ^ J 1<{ ak <. s pî ! x ! ! ' >1 y\iN n > î ii # â» /1 <. i (R Γ}'.)( 1 -p ï- -S.biît"2-CS:yîî ipirîoiy fed-jä îONhsiOk:8«ÎÎ8-3"d}· I Μ’ I ,.2,4 -:)'ÎStSÎC'h ># if )”08- Λ-f I 5 'A-^^-'h^hîhÂï'aJïhhk.tghâsoh.Aiih.okRtvdia-; sh#t*fth'dio-3 :ih:k:î'a»vy\ (Λ:)Α*'(1 -1 «\»dodp'fToM ' '- s3>\ a/rhy y h -* a >- s î> ~ ^ ii'.-'d \ώ·ιί *'* (,ÿ)..3 -{S -u'{ l-akrjfef|pjfroi>(làî'.i-R)!rt3®dlhinîÎtî<i){ï<»ksH<>!«:-à-d ;-1 H~ î .2,4--ínatok .#ïAR-i>fe .\' i^i-ü ä-akriioi'pirsyäsd·'''' Jk»v,"' Λ .okít# ü- ^ o' 1 ff !.' R 5¾ :&?d *5< klf> ^ N ΐ .A^kü í^VilotfefoyU'ha ' 'ΓκΟΌ .'">/> 'ss'\ lus ' -ih' Î ,'í ' 2 5 tn;ss:öl'Myh*hKUs; iRV-3'i ;-<_(! 'akí’ífes4pirroií«5«-2-U)meios;sdxökfe<dm'k-H}- î/â^ 2,4-ttjasoRSCdí/)or; (Λ4-4-5, h:(ä -«xetakrifeilpïtffthdûî·.»' iR^mksoissoksrsftho- '- 4>-1 //· RÀ k-äfiaskok5pi./r#s>s:5 ,ο, s j <v* ,sk,!kul$'Bss>l\ku :^ilXîia^s^m}tto)ÎÂôklsÂc3'SÎ.>»l^· ί· ;<( S ·<.( I -íaeíakí ik«s^jr«>lj<iüi*3'th»xi)s2ok«u>UH'3*íl)-1 ?At ,*'.*Μτ»*οΚχ4&}*®βί· tCy ''5. S-\sA5 'fd-ΐ ''JU'U s'liJs ï'i'>iî'N\kî,iK'!r>i?Î>Kiî>o (1¾ ' 4V1 -k I 3 vUít (,»#-'! Bid,*?'\ «, \ m „ « V. S Λ. ' ' λ viK ΛΤ' V.* í ' ' í "»* 4 c·' Í*V to ^'í.Ϊ-'*i.*'í.V'íí;ϊΊ'ίΠΡ'-ί'*^'*3 'ùr-?- 'aâïîf’x'iWkiïiN' !í’' ï 'h'í/'i·!,- '·'..oxul-M"*,*/yon, *S'í-3-(§·*{i -a.knkdlpijfyoHJin- '-ükí\i)-í J-numriöns· 6 -d V s # È k-s -uis.î:ok3U AdK-sv. ίΛ'ΐ 3-í^-ií i akiiU>'is"v>"'\Kn'^*ii<&tn'íi'»*“! '-iSiU^k'd-n-n-di-ki-l,. ,-s *\«\í 's,-kí!'!S!! í-£f--M Hí !'akrii«:sj:si;r!/!kitn~3'lj)ö>f)'7'r:!»i>H<if'k[noih“i-5ti'lK"ki.4'tria?.i'ii-^M/0·'^ 1 .(HimiMss* I ^kdiotM'-aíei^jirMÚIin^-^ wxOyvkmoha--)· H-s //· 5 -'-- 4··κ os?<d· >Hfc s-cu- -,< i .a0HAS}' ?-akrtioiM»fix«sl8^él.ldin-3<H)ös0í2oMfio}jn->'’Ü>'i /·/· 1,::.4-Uuuoi-ck ?ís on; ·;,( I *({{3S,-*$y I ^krito^»m#||^«ßdio*3vy)o^i>Ueldß«iim*3«·}^- i tl· k'2,4-ma2xd· >{·*·** j--ob*: {^V3^^{0^lilolíP^M5y^*í“jD»s*11urtrUoKinoíl,í"3‘ií)"l//‘ls284‘lr^2ol*5<4/í)'OV*i ,Nv'-s ä-5« u1skMk>ik>inoiym-.#''5i>ammct'?'ituoro'Ok'f5i'ä!r ' Μ>·|»# HH fn-vul Ή' kon. 5 s>ki' ; ·;{ > 4 s- ï H- ! ,2,<Μη«%υ} - h4 A H>«: Í*>-3-{Mi l^kriUí»p*ncoíkíji>>3-í^lS^f-fl8wriχοΗκ>!Η3Η)-1 //-K2,4-uüäAd-HANter,: ; ..<{; -àkriùôlpîfToiysn· >-ól>&ms:n>}^?'k,iynko>káK>HB'3'l?)' ; N- s <2<4-laa£Ouy 4 k j-c>u; /s>3.r i.({} ^k«5ö«pm4idlB· «· * -HMm»>]-5í4//H>ík t ,^3^-1 .{(I -akHuílpHclsdiu.- J-il^Â^P-k^ïAïkMïoHo^-iJ)* i H-Í ,.2,4-¾ iaad^wHsö:; ;.S>>-i I-<(I-ufcn^oilpîtTôiy*8*3-H'^Âp)?S-m«Joxba>k«^*»-5-iO·5rt-l ;-W î <6'(( i -akjril«ï'îp îr»ik^l>ilî®siH^ifî»rtdâ»' MO' i&\t2J'tó8xoU$í4ff)-<M: * «ta n«}lp!rmiym-.Vi!>ft*i)p«tdi»-2.UV i /H ,^inaxo05<4/-^o»: s^*Wi4(i-(-^-fc5,^^1)PÎRoiyi,t'î'âî^î)î?okâno}fev^ÎV“'4^î<iw‘3ÎÎ',''!'iWf*aa^'3''0n* (\ -(( \.(;kkk>fac??H}pÙKï!i-:k!v J-MVuH«io}t?okii\oÜR-Â-Ujh2.4'dlftjÂslMrî^^x^t#l*4!^ÂI ; î -(( i .akrdodpiperkK»«:Mljofc uHiMfa-b»· 3 -d)· V' \ < j U -Í '5 «u» 1 il ié> 's ku' X ' ' ' ' i»' * ' **-* : 5 *·** ' \ ( J ! T *V S 0-3 ' ,!!,<. S·»' 1 ' ' ' 4 !' d 1' '» { ,,C.O. J-vB, 3¾ silbfek^Biyiletek^:fc#Kán;s. 3¾ cbSbbi vn»vüie}«H vagy ,ia»t<»í)efe^b&nn5iA' ik4«ek és ùz îk'ikhs vígvöiy^k, lauïosaereK. vagv sisetcoixoft^ek ΙΪ,,Λκ 3:> ïgèi^ü^a sserinti ve^ôk'i, <»œ\y ï6j-?-(l-<ÇÎ -3kt«uiipirroHd«b3.il)ox0teokM«^0' 1 i ,2,4-:03^4-0(4)1),03, îauïomctje vâgy a ^gvSist-v^ immœr tyù&M^g dfegMhsîésgÉ lai A?, l: iBcBypcnt szúrni vcsgyôkï, anseiy (5}·3-Π-((1-8^ϋοίίρ;π<^4ίπ··ί iOamaxiOkokinoHn-o-U)' î s ;? A-tris^d-iï4/i)o>a. :3u?<5oïscjc vagy a vcgyüiet ïansoîBcr gyögyás^klap efk^KlhaSÔ ^éja. n<A ! „ [H s,vi ( , J'V' iMS ^ - uo.< ) 1 ' Vvirtl^iMOlSr -VM1X4mm^î 14φ<Μ,mrntmmmgy:a vagyuk* vagy îsnwu«riy%#«mliäg eikspölÄs#ä. n \ l ^rtMn'î » A'f> i> va'Ot, cl ^ ' M s : f ‘ O {'« mtm a,n " 'd> 1,2,4-tîi&2»l-5{4//H>Jk vagya *«gyUiet vsigÿ «môm^ g>-og>4s«idlag »lfoga<lha?ô ?ôja, te s. sg^pöot vagyükig î j «à ky? Ips ï^<ïlïâiïï ~2> ^ ?I^î>?< s S - ÖutM Ikô fe I í5«ll ?:s^ 3 - 'Ébi <'i' \^dtevsobabteVon. íaví-om®;!« vagy a vsgybkt vagy isagogvaf gyégyteabkíg elkîgadhaks sója. H>. λ\λ j^nvp^nl ^Acrsiïîî wgyilk'g axidy ib'id-a s-kbakrlioifpimikstio. MdoimxAk-sUio: 'okn-dio. χ&Η)*$-&*>^Φβι&^«^|βζ$|βΰβ^Η^θηκ^Β v&gy & vegyülj v&gy îauiossis'gyógyásaaaiiag dagadható soja. :te âa i U"^vitv\,s' ομΙμν '.I ! A iUnï »'* Ί* ' K\ 'L« 'M'y « dyb iW*1 j3.^M«KOi»3{4*7On» ía«kíí«es|!S vagy s vsgyblet vagy {äutom^^p^gy^^ttikg elfogadható sOj». ^ ^ e» ' h i 'X i i d, 3 V ! f<! 5p îiîhiâi« y* « x>( " kióHaaKmoms·' '·* oV5 «“ 1.2d·îrsa?.«>kH4£0· ou, ta«î«mô|je a v«gpkt hxiksmvt i& Ä* am% ppt^vtó^^íTr^tó«^3-«^*xí)-8Af^íxokmoHn^ ^|||*I7MX&khiiû-StëHï'mt tavK»m<îr!0 vagy a vagyuk* vagy j&ütoin·:* gyógváx.ía?d&g «{fogadható sója. 2« \f ".'SV' !'.> * i . ' <h ' J | á 1 1' »' J ' í* N |Yí.\íO0 r3^!fl“isaiomisip v&gy a \ígyühi vagy iaubsaasr p#gyls28iOa|:41iföiad!íaík:MA
- 21. Myo&yas&sU bvaabméay. /amely ;w 1-20 igihvy^m&k bdraidyike szsdtó-ms^atámott: mihssx-ri vagy j$\tgyás29ttOag «UogadhatO sót as gyégytósdlag elfogadh&îô seg&laay&gol ssnahsag; Î2 3 ' o> gi'"i\">>'u'i\ l"n\ls \c a* « μ vO?'U V „ «lv> v v ·. s >o „ v. < .mass gifdgsdkaîô só gyógymódra lônènê &lfatí«a*ásr&.
- 23. Âz 1*20. igèivypo.stok bikrodyike «rist ínegíhsiáfOiKítt vegyülj naacmet vagy gyvigyásíadkg elfogadható s6 5 típus« tuUhrzékefiységi reakciók, autómé«« betegségek, gyulladásos betegségek, t&k svvssfKkviaiá proliférai iv saaGdki-Ka^égek kózö) választott betegség· reede «estessé g vagy slkspo· kcAikaaska« iOnéiso slkalmasbhfs. 24. Λ:··: l-óó. leéri ypomok bámAyiite szerbi meghatározóit vsgy-'ksk laetmiíei vagy gyegv Amikig #ky>..4k. h 3 ΊίΛ' vhá, «.'' * steps ds'îteïtï'.a ï.s o. «mu > H.W". a iltmk's v?»' kgxisz eravoaíósjs^ lopva ivephriiís. pszoriázis. Immun lTorobodtopémás puipura, gyulladásos bélbetegség, •krv%ik«x ok-ieukssv nsdèKtegteg, $fogvu-v mdwm?. rgvnAhsi.· m*vt'jx.uK.», {te,vs4te grad d g tsétegség, pemphigus vulgaris. kfiopftife ptomejíes Omíádenopáüa, ateroszJOerőxis. miokarcNélte lofarkti^ í?v teslxdia köaül választó« !xavgwg< rasxkkencwäg vagy állapot ktavívSek-aa tô*ît?no alkasmaza^ :"2f,;%·.:, kICk |géky|g»ïlïik Ä«il» sdídst :m#g|.IÄl:M. yadëdkï' vágy gÿkpfevadlâg elfoga«fiat6 vv B-^jtes Hmi3;aa; dóikká, bovtosb {«akónua aashipkv kol»l yalaaHód kdk^4|. fíííxkilviíssisé'a vagy áiUipoi kf&?lászboTs χΐτιέκο askíosRazási's. 26 V, V V t l,U> '·'(· W*v H.'VI V W '« * " eitogaiUsaió só hatásos sixavsiyhvgvavk éa kplább vjyy további gy-gv^aaiiiag aktiv «n>sg looávvacxou.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361776445P | 2013-03-11 | 2013-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE032720T2 true HUE032720T2 (hu) | 2017-10-30 |
Family
ID=50543655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE14719130A HUE032720T2 (hu) | 2013-03-11 | 2014-03-10 | Piridinil- és kondenzált piridinil-triazolon származékok |
Country Status (42)
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2892900T (pt) | 2012-09-10 | 2017-11-06 | Principia Biopharma Inc | Compostos de pirazolopirimidina como inibidores de cinase |
JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
CN104447530A (zh) * | 2014-12-11 | 2015-03-25 | 苏州欧凯医药技术有限公司 | 4-甲基-2,6-二羧基吡啶的制备方法 |
CN107257686B (zh) * | 2014-12-18 | 2021-01-29 | 普林斯匹亚生物制药公司 | 天疱疮的治疗 |
TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
US10836745B2 (en) * | 2015-12-24 | 2020-11-17 | Takeda Pharmaceutical Company Limited | Cocrystal, production method thereof, and medicament containing cocrystal |
HUE052893T2 (hu) * | 2016-01-13 | 2021-05-28 | Acerta Pharma Bv | Antifolát és BTK-gátló terápiás kombinációi |
WO2017173111A1 (en) | 2016-03-31 | 2017-10-05 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
SG11201811255WA (en) | 2016-06-29 | 2019-01-30 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
WO2020021447A1 (en) | 2018-07-25 | 2020-01-30 | Novartis Ag | Nlrp3 inflammasome inhibitors |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP3949963A4 (en) * | 2019-04-02 | 2023-01-04 | Yonsei University, University-Industry Foundation(UIF). | NEW COMPOUND AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES COMPRISING THIS AS AN ACTIVE PRINCIPLE |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AU2021325431B2 (en) | 2020-08-14 | 2024-01-18 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
TW202406550A (zh) | 2022-08-03 | 2024-02-16 | 瑞士商諾華公司 | Nlrp3炎性小體抑制劑 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
US5733849A (en) * | 1996-03-15 | 1998-03-31 | Rohm And Haas Company | Halopyridyl triazolinone herbicides and herbicidal use thereof |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
IL139080A0 (en) | 1998-04-17 | 2001-11-25 | Parker Hughes Inst | Btx inhibitors and methods for their indentification and use |
CA2422367C (en) * | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002050071A1 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
EP1981888A4 (en) | 2006-01-13 | 2010-10-13 | Pharmacyclics Inc | TYROSINE KINASE INHIBITORS AND USES THEREOF |
WO2007139967A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
WO2007147771A2 (en) | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
SG10201508035TA (en) | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
EP2229390B1 (en) | 2007-12-14 | 2014-04-09 | F. Hoffmann-La Roche AG | Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives |
BRPI0907915A2 (pt) | 2008-02-05 | 2015-07-28 | Hoffmann La Rocha Ag F | Piridinonas e piridazinonas |
UA103327C2 (en) | 2008-06-24 | 2013-10-10 | Ф. Хоффманн-Ля Рош Аг | Substituted pyridin-2-ones and pyridazin-3-ones |
WO2010000633A1 (en) | 2008-07-02 | 2010-01-07 | F. Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
EP2307413B1 (en) | 2008-07-15 | 2015-09-09 | F. Hoffmann-La Roche AG | Novel phenyl-imidazopyridines and pyridazines |
WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
AU2011253003B2 (en) | 2010-05-13 | 2014-05-01 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
MX367623B (es) | 2010-10-20 | 2019-08-29 | Gruenenthal Gmbh | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. |
WO2012064972A2 (en) | 2010-11-10 | 2012-05-18 | Stc.Unm | Aerosol reduction/expansion synthesis (a-res) for zero valent metal particles |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
-
2014
- 2014-03-05 JO JOP/2014/0070A patent/JO3377B1/ar active
- 2014-03-10 BR BR112015020264-0A patent/BR112015020264B1/pt active IP Right Grant
- 2014-03-10 AU AU2014249248A patent/AU2014249248B2/en active Active
- 2014-03-10 UA UAA201507597A patent/UA114944C2/uk unknown
- 2014-03-10 TW TW103108214A patent/TWI637950B/zh active
- 2014-03-10 GE GEAP201413953A patent/GEP201706778B/en unknown
- 2014-03-10 CN CN201480012902.5A patent/CN105121427B/zh active Active
- 2014-03-10 SG SG11201506112QA patent/SG11201506112QA/en unknown
- 2014-03-10 KR KR1020157028600A patent/KR102300612B1/ko active IP Right Grant
- 2014-03-10 LT LTEP14719130.8T patent/LT2970202T/lt unknown
- 2014-03-10 RS RS20170414A patent/RS55879B1/sr unknown
- 2014-03-10 JP JP2016501072A patent/JP6271700B2/ja active Active
- 2014-03-10 AP AP2015008646A patent/AP2015008646A0/xx unknown
- 2014-03-10 MA MA38391A patent/MA38391B1/fr unknown
- 2014-03-10 WO PCT/US2014/022801 patent/WO2014164558A1/en active Application Filing
- 2014-03-10 ME MEP-2017-98A patent/ME02693B/me unknown
- 2014-03-10 MY MYPI2015703082A patent/MY183927A/en unknown
- 2014-03-10 ES ES14719130.8T patent/ES2624439T3/es active Active
- 2014-03-10 UY UY0001035376A patent/UY35376A/es not_active Application Discontinuation
- 2014-03-10 ES ES17152008T patent/ES2714166T3/es active Active
- 2014-03-10 PT PT147191308T patent/PT2970202T/pt unknown
- 2014-03-10 HU HUE14719130A patent/HUE032720T2/hu unknown
- 2014-03-10 DK DK14719130.8T patent/DK2970202T3/en active
- 2014-03-10 EP EP17152008.3A patent/EP3235814B1/en active Active
- 2014-03-10 SI SI201430203A patent/SI2970202T1/sl unknown
- 2014-03-10 EP EP14719130.8A patent/EP2970202B1/en active Active
- 2014-03-10 EA EA201591686A patent/EA028584B1/ru unknown
- 2014-03-10 PL PL14719130T patent/PL2970202T3/pl unknown
- 2014-03-10 US US14/203,366 patent/US9402841B2/en active Active
- 2014-03-10 MX MX2015011533A patent/MX364527B/es active IP Right Grant
- 2014-03-10 PE PE2015001905A patent/PE20151889A1/es active IP Right Grant
- 2014-03-10 CA CA2899948A patent/CA2899948C/en active Active
- 2014-03-10 AR ARP140100805A patent/AR095198A1/es active IP Right Grant
-
2015
- 2015-08-04 IL IL240353A patent/IL240353B/en active IP Right Grant
- 2015-08-06 DO DO2015000184A patent/DOP2015000184A/es unknown
- 2015-08-11 TN TN2015000342A patent/TN2015000342A1/en unknown
- 2015-08-19 ZA ZA2015/05996A patent/ZA201505996B/en unknown
- 2015-08-24 CL CL2015002370A patent/CL2015002370A1/es unknown
- 2015-09-10 CR CR20150470A patent/CR20150470A/es unknown
- 2015-09-10 PH PH12015502046A patent/PH12015502046A1/en unknown
- 2015-10-08 EC ECIEPI201542779A patent/ECSP15042779A/es unknown
-
2016
- 2016-06-29 US US15/197,051 patent/US9801872B2/en active Active
- 2016-07-12 HK HK16108174.3A patent/HK1220183A1/zh unknown
-
2017
- 2017-04-20 HR HRP20170622TT patent/HRP20170622T1/hr unknown
- 2017-04-25 CY CY20171100458T patent/CY1119356T1/el unknown
- 2017-09-27 US US15/717,624 patent/US10307414B2/en active Active
- 2017-12-27 JP JP2017252294A patent/JP6462842B2/ja active Active
-
2018
- 2018-04-06 HK HK18104553.1A patent/HK1245256B/zh unknown
-
2019
- 2019-04-03 US US16/374,430 patent/US20190224190A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10307414B2 (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
EP3489236B1 (en) | Process for the preparation of fused heteroaromatic pyrrolidinones | |
US9365566B2 (en) | Cinnoline derivatives | |
TW201206923A (en) | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | |
US9663514B2 (en) | Substituted 6-aza-isoindolin-1-one derivatives | |
AU2013288895A1 (en) | Azaindole derivatives which act as PI3K inhibitors | |
WO2020198053A1 (en) | 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases | |
NZ710852B2 (en) | Pyridinyl and fused pyridinyl triazolone derivatives |